Tactiva Therapeutics

Tactiva Therapeutics Reports Data Highlighting a Novel Dual CD4/CD8 T Cell Receptor with Potential for Use Against a Broad Range of Cancers

Tactiva Therapeutics today reported on its unique, dual enhanced adoptive cell therapy (DEACT) platform, incorporating its proprietary, engineered CD4/CD8 T cell receptors (TCR) with potential broad utility in cancer immunotherapy, including melanoma and ovarian cancer. A late breaking abstract... - April 05, 2017